What side effects are associated with this type of intervention?

Common treatments for bile duct cancer include chemotherapy regimens such as gemcitabine combined with cisplatin, and targeted therapies like PARP inhibitors (e.g., Olaparib). The side effects of these treatments can vary. For chemotherapy, common side effects include nausea, vomiting, fatigue, and hematologic toxicities such as anemia, thrombocytopenia, and neutropenia. PARP inhibitors like Olaparib can cause similar hematologic side effects, including anemia, thrombocytopenia, and neutropenia, as well as non-hematologic effects like nausea, anorexia, and asthenia. These side effects are generally manageable with dose modifications and supportive care.

What prior FDA approvals exist?

There is limited specific information on prior FDA approvals for PARP inhibitors like Olaparib in the treatment of bile duct cancer. However, Olaparib is being studied for its efficacy in treating metastatic biliary tract cancer with aberrant DNA repair gene mutations. Generally, treatments for advanced biliary tract cancers have included chemotherapy regimens such as gemcitabine combined with cisplatin, and newer approaches are exploring targeted therapies and immunotherapies.

What other types of research exist?

Promising novel alternatives to Olaparib for bile duct cancer patients include: <ol> <li>Pemigatinib - an FGFR inhibitor shown to be effective in patients with FGFR2 gene fusions.</li> <li></li> </ol> Ivosidenib - an IDH1 inhibitor for patients with IDH1 mutations. 3. Nivolumab - a PD-1 inhibitor that has shown efficacy in advanced refractory biliary tract cancer. 4. Durvalumab combined with gemcitabine and cisplatin - an immunotherapy approach that has shown promise in advanced biliary tract cancer.

← Back to Search

PARP Inhibitor

Olaparib for Biliary Tract Cancer

Q: What is the mechanism of action of this treatment?

The most common treatments for bile duct cancer include chemotherapy, targeted therapy, and PARP inhibitors like Olaparib. Chemotherapy drugs, such as gemcitabine and cisplatin, work by damaging the DNA of cancer cells, preventing them from dividing and growing. Targeted therapies, like FGFR inhibitors, block specific molecules involved in cancer cell growth and survival. PARP inhibitors, such as Olaparib, prevent the repair of single-strand DNA breaks in cancer cells with defective DNA repair mechanisms, leading to cell death. These treatments are significant for bile duct cancer patients as they offer tailored approaches that can improve outcomes, especially in those with specific genetic mutations.

New York, NY

Phase 2

Recruiting

Led By Daniel H Ahn

Research Sponsored by Academic and Community Cancer Research United

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histological or cytological documentation of metastatic adenocarcinoma of the biliary tract

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)

Must not have

Concomitant use of known strong or moderate CYP3A inducers

Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 years

Awards & highlights

No Placebo-Only Group

Summary

This trial studies how well olaparib works in patients with advanced biliary tract cancer and specific DNA repair gene mutations. Olaparib may help stop cancer growth by blocking enzymes needed for cell repair. The trial aims to see if this treatment can improve survival and response rates.

See full description

Who is the study for?

Adults with metastatic biliary tract cancer and specific DNA repair gene mutations can join. They must have a certain level of blood cells, organ function, and life expectancy over 16 weeks. Participants need to provide samples for research and not be pregnant or breastfeeding. Those with severe heart conditions, recent surgeries, uncontrolled infections or hypertension, prior PARP inhibitor treatment like olaparib, other cancers or treatments within the last month are excluded.Check my eligibility

What is being tested?

The trial is testing Olaparib's effectiveness on patients with advanced biliary tract cancer that has spread and who have abnormal DNA repair genes. It involves MRI and CT scans for monitoring tumor response to Olaparib which blocks enzymes needed by cancer cells to grow.See study design

What are the potential side effects?

Olaparib may cause side effects such as nausea, vomiting, fatigue, anemia (low red blood cell counts), neutropenia (low white blood cell counts), thrombocytopenia (low platelet counts), digestive issues like indigestion or diarrhea, changes in taste sensation and risk of infection.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer, originating in the bile ducts, has spread to other parts.

show original

Select...

My liver enzymes are within the required range for the trial.

show original

Select...

I have genetic changes linked to how my cells repair DNA.

show original

Select...

My cancer can be measured by tests.

show original

Select...

My kidneys are functioning well, with a creatinine clearance of at least 51 mL/min.

show original

Select...

I am 18 years old or older.

show original

Select...

I can take care of myself and am up and about more than half of my waking hours.

show original

Select...

My hemoglobin level is at least 9.0 g/dL and I haven't had a blood transfusion in the last 28 days.

show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am not taking any strong or moderate drugs that affect liver enzymes.

show original

Select...

I understand the study drug's effects on unborn babies are unknown.

show original

Select...

I have not had major surgery or a serious injury in the last 28 days.

show original

Select...

I am immunocompromised or HIV positive and on antiretroviral therapy.

show original

Select...

I have previously been treated with a PARP inhibitor.

show original

Select...

I am experiencing moderate to severe dehydration.

show original

Select...

I require dialysis for kidney failure.

show original

Select...

I have a condition that affects how my body absorbs medication.

show original

Select...

I have been diagnosed with MDS/AML or show signs of it.

show original

Select...

I have or had a pheochromocytoma.

show original

Select...

I currently have symptoms of interstitial lung disease.

show original

Select...

I haven't had serious bleeding issues in the last month.

show original

Select...

I have heart failure that affects my daily activities.

show original

Select...

I am on medication that affects my heart's rhythm.

show original

Select...

I have fluid in my chest or abdomen causing significant breathing problems.

show original

Select...

My blood pressure is not controlled and is considered severe.

show original

Select...

I am on medication for seizures.

show original

Select...

My condition did not improve after platinum-based chemotherapy.

show original

Select...

I cannot take medicine by mouth.

show original

Select...

I have a wound, ulcer, or bone fracture that hasn't healed.

show original

Select...

I do not have a serious ongoing infection.

show original

Select...

I have had an organ transplant, bone marrow transplant, or cord blood transplantation.

show original

Select...

I am not taking strong or moderate CYP3A inhibitors.

show original

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Progression-free survival (PFS) at first scan

Secondary study objectives

Duration of response (DoR)

Incidence of adverse events

Objective response rate

+2 more

Other study objectives

Mutational signatures

Presence of mutations and mutational signatures

Prevalence of mutations

+1 more

Side effects data

From 2022 Phase 4 trial • 202 Patients • NCT04330040

100%

Asthenia

100%

Retinal vascular occlusion

100%

80%

60%

40%

20%

Study treatment Arm

Both Ovarian Cancer and Breast Cancer

Ovarian Cancer

Breast Cancer

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (olaparib)Experimental Treatment4 Interventions

Patients receive olaparib PO BID on days 1-28. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan or MRI throughout the trial, and collection of blood and tissue samples on study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Magnetic Resonance Imaging

2020

Completed Phase 3

~1180

Computed Tomography

2017

Completed Phase 2

~2440

Olaparib

2017

Completed Phase 4

~2310

Biospecimen Collection

2004

Completed Phase 3

~1810

0 / 31Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for bile duct cancer include chemotherapy, targeted therapy, and PARP inhibitors like Olaparib. Chemotherapy drugs, such as gemcitabine and cisplatin, work by damaging the DNA of cancer cells, preventing them from dividing and growing. Targeted therapies, like FGFR inhibitors, block specific molecules involved in cancer cell growth and survival. PARP inhibitors, such as Olaparib, prevent the repair of single-strand DNA breaks in cancer cells with defective DNA repair mechanisms, leading to cell death. These treatments are significant for bile duct cancer patients as they offer tailored approaches that can improve outcomes, especially in those with specific genetic mutations.

Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.